RICHARD M RANSOHOFF, MD
Neurology at Euclid Ave, Cleveland, OH
License number
Ohio 35043572
Category
Neurology
Type
Neurology
Address
Address
9500 Euclid Ave, Cleveland, OH 44195
Phone
(800) 223-2273
Personal information
See more information about RICHARD M RANSOHOFF at radaris.comName
Address
Phone
19850 Marchmont Rd, Shaker Heights, OH 44122
17325 Euclid Ave, Cleveland, OH 44112
19850 Marchmont Rd, Beachwood, OH 44122
2973 Montgomery Ave, Beachwood, OH 44122
Organization information
See more information about RICHARD M RANSOHOFF at bizstanding.comCleveland Clinic Foundation - Richard M Ransohoff MD
9500 Euclid Ave #U10, Cleveland, OH 44195
Categories:
Neurology Physicians & Surgeons, Physicians & Surgeons
Phone:
(216) 444-8939 (Phone)
Professional information
Richard M Ransohoff, Cleveland OH
Specialties:
Neurologist
Address:
9500 Euclid Ave, Cleveland, OH 44195
Education:
Case Western Reserve University, School of Medicine - Doctor of Medicine
University Hospitals - Case Medical Center - Fellowship - Molecular Biology
Cleveland Clinic Hospital - Residency - Neurology
Mount Sinai Hospital - Residency - Internal Medicine
University Hospitals - Case Medical Center - Fellowship - Molecular Biology
Cleveland Clinic Hospital - Residency - Neurology
Mount Sinai Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Dr. Richard M Ransohoff, Cleveland OH - MD (Doctor of Medicine)
Specialties:
Internal Medicine, Neurology, Neuropsychiatry (Neurology)
Address:
Cleveland Clinic Neurology
9500 Euclid Ave, Cleveland 44195
(216) 444-2200 (Phone)
9500 Euclid Ave SUITE S90, Cleveland 44195
(216) 444-2200 (Phone)
9500 Euclid Ave, Cleveland 44195
(216) 444-2200 (Phone)
9500 Euclid Ave SUITE S90, Cleveland 44195
(216) 444-2200 (Phone)
Certifications:
Internal Medicine, 1981, Neurology, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Cleveland Clinic Neurology
9500 Euclid Ave, Cleveland 44195
9500 Euclid Ave SUITE S90, Cleveland 44195
Cleveland Clinic
9500 Euclid Ave, Cleveland 44195
9500 Euclid Ave, Cleveland 44195
9500 Euclid Ave SUITE S90, Cleveland 44195
Cleveland Clinic
9500 Euclid Ave, Cleveland 44195
Education:
Medical School
Case Western Reserve University School Of Medicine
Graduated: 1978
Cleveland Clinic
Graduated: 1984
Mt Sinai Hospital
Graduated: 1981
Case West Res University School Med
Graduated: 1989
Case Western Reserve University School Of Medicine
Graduated: 1978
Cleveland Clinic
Graduated: 1984
Mt Sinai Hospital
Graduated: 1981
Case West Res University School Med
Graduated: 1989
Dna Encoding A Chemokine, Beta R1, Comprising The Beta R1 Promoter
US Patent:
5977334, Nov 2, 1999
Filed:
Sep 11, 1997
Appl. No.:
8/927722
Inventors:
Richard Ransohoff - Shaker Heights OH
Sandhya Rani - South Euclid OH
Sandhya Rani - South Euclid OH
Assignee:
The Cleveland Clinic Foundation - Cleveland OH
International Classification:
C12N 1519, C07K 1452
US Classification:
536 2351
Abstract:
The invention provides a chemokine designated Beta R1, whose production in T cells, astrocytes, a fibroblasts is preferentially induced by IFN-. beta. as compared to IFN-. alpha. A cDNA encoding the Beta R1 polypeptide and comprising the endogenous Beta R1 promoter is described. When coupled to a reporter gene, the promoter sequence may be used to screen for mimics of IFN-. beta. activity.
Richard Milton Ransohoff, Cleveland OH
Specialties:
Internal Medicine, Neurology
Work:
Cleveland Clinic
9500 Euclid Ave, Cleveland, OH 44185
9500 Euclid Ave, Cleveland, OH 44185
Education:
Case Western Reserve University(1978)
Beta R-1 Chemokine
US Patent:
6414118, Jul 2, 2002
Filed:
Aug 20, 1999
Appl. No.:
09/378069
Inventors:
Richard Ransohoff - Shaker Heights OH
Sandhya Rani - South Euclid OH
Sandhya Rani - South Euclid OH
Assignee:
The Cleveland Clinic Foundation - Cleveland OH
International Classification:
C07K 1400
US Classification:
530350, 435 691, 4352523, 4353201, 536 2351, 536 234
Abstract:
The present invention provides an isolated polypeptide, designated Beta R1, whose production is selectively induced by IFN- as compared to IFN-. The Beta R1 polypeptide is a chemokine whose expression is stimulated in T cells, astrocytes, and fibroblasts that have beenâexposed to IFN-. The present invention also provides an isolated polynucleotide that encodes the Beta R1 polypeptide and an isolated polynucleotide that encodes the Beta R1 promoter. The present invention also provides a method of identifying putative IFN- mimics. In one embodiment, the method comprises the steps of providing cultured cells transfected with a polynucleotide construct that comprises a DNA sequence that encodes the Beta R1 promoter operatively linked to a reporter gene that encodes an assayable product; treating the transfected cells with the putative IFN- mimic; and detecting the assayable product produced by the treated cells. Synthesis of the assayable product by the cells treated with the putative IFN- mimic is indicative of the IFN- response. In another embodiment, the method comprises the steps of treating cultured cells with the putative IFN- mimic and detecting the presence of the Beta R1 transcript in the treated cells; wherein the presence of the Beta R1 transcript in the treated cells is indicative of the IFN- response.
Method For Predicting A Therapy Response In Subjects With Multiple Sclerosis
US Patent:
2013008, Apr 11, 2013
Filed:
Jun 17, 2011
Appl. No.:
13/704752
Inventors:
Richard A. Rudick - Solon OH, US
Richard M. Ransohoff - Shaker Heights OH, US
Richard M. Ransohoff - Shaker Heights OH, US
International Classification:
C12Q 1/68
US Classification:
424 856, 506 9
Abstract:
A method is provided for determining the efficacy of interferon-beta (IFN-β) therapy in a subject with multiple sclerosis. One step of the method can include obtaining a biological sample from the subject. After obtaining the biological sample, the expression level of at least one interferon-regulated gene (IRG) and/or variant thereof can be determined. Increased or decreased expression of the at least one IRG and/or variant thereof as compared to a control may indicate that the subject will respond poorly to IFN-β therapy.